An Expert’s View on the Application of TIM Technology in the Development of Oral Drug Products
Molecular Pharmaceutics · 2026
DOI: 10.1021/acs.molpharmaceut.5c01197 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Álvaro López Mármol und 12 weiteren Autor:innen. Beteiligte Einrichtung: Synthetic Molecules CMC R&D, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein 67061, Germany. Hauptthemen laut MEDLINE: Drug Development, Gastrointestinal Tract. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: Engineering and Physical Sciences Research Council.
Abstract (Originalsprache)
The TIM models tiny-TIM and TIM-1 enable a physiologically relevant in vitro simulation of drug product performance in the upper human gastrointestinal tract under various intake conditions. These systems are considered to be among the most biorelevant oral in vitro models commercially available on the market. This White Paper has been written by a group of experienced users of the TIM systems and shall provide an independent and comprehensive review of the various applications of these systems in the field of pharmaceutical development, as well as current limitations of the systems and how to address them. Recent improvements in the function of the TIM systems, as well as in the use of the data generated, have expanded the application of TIM systems beyond the prediction of food effects and the support of formulation development. For instance, the incorporation of intraluminal concentration and bioaccessibility profiles into in silico models can significantly improve clinical PK predictions and thereby inform decision-making in drug product development in many ways. This work provides an overview of the TIM systems in preclinical and clinical drug product development, supported by selected case studies of various applications. Furthermore, regulatory aspects, the contribution to reducing animal experimentation (3R), and options for future improvement of the TIM systems are highlighted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Synthetic Molecules CMC R&D, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein 67061, Germany.
- Global Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK102NA, U.K.
- Material and Analytical Sciences, Research and Development, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut 06877, United States.
- Pfizer, Drug Product Design, Pfizer Belgium, Hermeslaan 11, Zaventem 1932, Belgium.
- Biowaived, GS.021 Discovery Park House, Ramsgate Road, Discovery Park, Sandwich CT139NJ, U.K.
- GlaxoSmithKline R&D, Biopharmaceutics, Drug Product Development, David Jack Research Centre Harris's Lane, Ware, Hertfordshire SG12 0GX, U.K.
ORCID-Profile: Álvaro López Mármol, Richard Barker, Robert Schwabe, Bart Hens, James M Butler, Hannah Batchelor
Förderung
- Engineering and Physical Sciences Research Council
Zitieren
APA
López Mármol, Á., Barker, R., Koziolek, M., Schwabe, R., Hens, B., Sarcevica, I., Butler, J. M., McAllister, M., Taylor, E., Chiang, P. C., Stainforth, N., Jones, E., & Batchelor, H. (2026). An Expert’s View on the Application of TIM Technology in the Development of Oral Drug Products. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01197
Vancouver
López Mármol Á, Barker R, Koziolek M, Schwabe R, Hens B, Sarcevica I, et al. An Expert’s View on the Application of TIM Technology in the Development of Oral Drug Products. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01197
BibTeX
@article{LpezMrmol2026,
author = {López Mármol, Álvaro and Barker, Richard and Koziolek, Mirko and Schwabe, Robert and Hens, Bart and Sarcevica, Inese and Butler, James M and McAllister, Mark and Taylor, Edward and Chiang, Po-Chang and Stainforth, Nick and Jones, Eleanor and Batchelor, Hannah},
title = {An Expert’s View on the Application of TIM Technology in the Development of Oral Drug Products},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.5c01197}
}
EUVIMED